News

Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 ...
Should Meta be worried? The Valve Deckard VR headset is shaping up to be a beast – here are 5 things we know
A leaked Valve Deckard concept (via Upload VR) boasted 2K LCD panels for its display setup, and was powered by a SnapDragon 8 ...